Taysha Gene Therapies, Inc.— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2025 - Q4(Oct 25 · Nov 25 · Dec 25)
Total Assets
$343M
↑+114.1% +$183Mvs FY2024
Total Liabilities
$96M
↑+8.5% +$8Mvs FY2024
Equity
$247M
↑+245.2% +$175Mvs FY2024
Cash
$320M
↑+130.0% +$181Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $343M | $160M |
| Current Assets | $325M | $142M |
| Cash | $320M | $139M |
| ST Investments | $0 | $0 |
| Receivables | $0 | $0 |
| Inventory | $0 | $0 |
| Other Current | $5M | $3M |
| Non-Current Assets | $19M | $18M |
| PPE | $7M | $7M |
| Goodwill | $0 | $0 |
| Intangibles | $0 | $0 |
| Investments | $0 | $0 |
| Other Non-Current | $12M | $11M |
| Total Liab+Eq | $343M | $160M |
| Current Liab. | $27M | $26M |
| Accounts Payable | $6M | $4M |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $0 | $10M |
| Other CL | $20M | $13M |
| Non-Current Liab. | $70M | $63M |
| Long-Term Debt | $50M | $44M |
| Other LT Liab. | $20M | $19M |
| Equity | $247M | $72M |
| Retained Earnings | $711M | $602M |
| Other Equity | $0 | $0 |
QuarterCharts · SEC EDGAR data · TSHA · Comparing FY2025 vs FY2024